Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 11/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.65 |
| ▸ | MAOA | P21397 | 2/20 | 0.65 |
| ▸ | MAOB | P27338 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | PIM1 | P11309 | 2/20 | 0.60 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12107351 | 1.00 | HPGD (1.00) | HPGDPTPN1MAOAMAOBPOLB | |
| SCHEMBL1299735 | 1.00 | HPGD (1.00) | HPGDPTPN1MAOAMAOBPOLB | |
| SCHEMBL30919372 | 0.81 | HPGD (0.68) | HPGDPOLBKDM4E | |
| SCHEMBL934310 | 0.79 | HPGD (1.00) | HPGDPTPN1MAOAMAOBPOLB | |
| SCHEMBL934311 | 0.79 | HPGD (1.00) | HPGDPTPN1MAOAMAOBPOLB | |
| SCHEMBL15421510 | 0.79 | HPGD (1.00) | HPGDPTPN1MAOAMAOBPOLB | |
| SCHEMBL1299891 | 0.79 | HPGD (1.00) | HPGDPTPN1MAOAMAOBPOLB | |
| SCHEMBL6865889 | 0.79 | HPGD (1.00) | HPGDPTPN1MAOAMAOBPOLB | |
| SCHEMBL1299892 | 0.79 | HPGD (1.00) | HPGDPTPN1MAOAMAOBPOLB | |
| SCHEMBL2029922 | 0.76 | HPGD (0.61) | HPGDPTPN1POLBPIM1PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2383263-B1 | NOVEL THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF | UNIV CHOSUN IACF (KR) | 2014-04-16 | — | — | EP | disclosed |
| US-8637558-B2 | Thiazolidinedione derivative and use thereof | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, CHOSUN UNIVERSITY (KR) | 2014-01-28 | — | — | US | disclosed |
| US-20110269954-A1 | NOVEL THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, CHOSUN UNIVERSITY (KR) | 2011-11-03 | — | — | US | disclosed |
| EP-2383263-A2 | NOVEL THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF | Industry-academic Cooperation Foundation, Chosun University (KR) | 2011-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269954-A1 | NOVEL THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF | HPGD, CYP27B1, GCDH | HPGD 1/4885PTPN1 2074/4885MAOA 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.